Results 171 to 180 of about 53,296 (261)

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

Cancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu, Xinhui Lv, Shunhao Zhang, Yafang Chen, Sicong Liu, Feiyang Song, Chunmei Zhao, Guihua Wang, Xudong Wang   +8 more
wiley   +1 more source

Correction to: Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study. [PDF]

Calcif Tissue Int
Schulz N, Asendorf T, van Wijnen P, Wilhelmi T, Müller-Ladner U, Lange U, Klemm P.   +6 more
europepmc   +1 more source

Treatment‐Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure

Cancer Science, EarlyView.
Immune surveillance of residual leukemic stem cells after tyrosine kinase inhibitor discontinuation involves coordinated NK‐cell, CTL, Treg, pDC, and neutrophil activity that predicts treatment‐free remission, while exhausted CTLs and Treg expansion predict relapse in chronic myeloid leukemia.
Hiroshi Ureshino, Shinya Kimura
wiley   +1 more source

Incidental treatment of granulomatosis with polyangiitis with a Janus Kinase inhibitor in a patient undergoing alopecia treatment. [PDF]

JAAD Case Rep
Mendez D, Xiang L, Bergfeld W.
europepmc   +1 more source

PABPC1 in Cancer: From a Translational Housekeeper to a Stress‐Responsive Regulatory Hub

Cancer Science, EarlyView.
PABPC1 shifts from a translational housekeeper to a stress‐responsive oncogenic hub via phase separation, PTMs, and non‐coding RNA crosstalk, selectively driving oncogene translation and therapy resistance in cancer. ABSTRACT PABPC1, long recognized as a constitutive translational housekeeper, has emerged as a stress‐responsive translational ...
Cuiwei Zhang, Ye Zhu, Wenbo Long
wiley   +1 more source

Ruxolitinib cream for the treatment of granuloma annulare

JAAD Case Reports
Austin J. Piontkowski, BS, Nancy Wei, MD, Aisha Mumtaz, MD, Nicholas Gulati, MD, PhD   +3 more
doaj   +1 more source

Treatment of Hailey-Hailey disease with the Janus kinase inhibitor abrocitinib: A case report. [PDF]

SAGE Open Med Case Rep
Gunyon M, Udupa M, Mahmood F, Foulkes WD, Pehr K, Netchiporouk E.   +5 more
europepmc   +1 more source

NFкB pathway suppression as a key driver of pacritinib response in high‐risk myelofibrosis

British Journal of Haematology, EarlyView.
R. Van Dijck, M. ter Borg, B. van der Holt, A. E. C. Broers, M. D. Hazenberg, J. J. Cornelissen, N. P. M. Schaap, E. de Pater, P. A. W. te Boekhorst   +8 more
wiley   +1 more source

A20 Inhibits IFN‐γ Signaling in Hepatocellular Carcinoma Cells by Binding to STAT1, Compromising Anti‐Tumor Immunity

Cancer Science, EarlyView.
A20 suppresses IFN‐γ signaling in HCC cells by binding to STAT1 through its ZnF7 domain, thereby reducing CXCL9, CXCL10, and HLA‐ABC expression, ultimately impairing CD8+ T‐cell‐mediated anti‐tumor immunity. ABSTRACT Immune checkpoint blockade (ICB) has demonstrated efficacy in clinical cancer therapy; however, a significant proportion of cancer ...
Yanlei Dong, Jing Yi, Ruoxuan Yang, Yingyue Wang, Zelong Ma, Hong Yuan, Meichen Song, Ying Xiao, Chun Guo, Jianing Wang, Xiaoyan Wang, Faliang Zhu, Lining Zhang, Yuchen Fan, Yongyu Shi   +14 more
wiley   +1 more source

Efficacy and safety of momelotinib in Janus kinase inhibitor-experienced Asian patients with myelofibrosis and anemia. [PDF]

Int J Hematol
Yoon SS, Chen CC, Lee SE, Chang H, Cheong JW, Hou HA, Lee WS, Lim SN, Moon JH, Ong KH, Dai Y, Liu C, Kawashima J, Goh YT.   +13 more
europepmc   +1 more source